NASDAQ | TSX: ACB
Investment in the region continues with the
launch of IndiMed, the company's first locally grown brand in
Germany
EDMONTON, AB, Jan. 23,
2025 /CNW/ - Aurora Cannabis Inc. (NASDAQ: ACB) (TSX:
ACB), the Canadian-based leading global medical cannabis company,
announces today the launch of the company's first German-cultivated
medical cannabis product, under the brand IndiMed. Manufactured at
Aurora's leading EU-GMP facility in Leuna, Germany, the new brand offers a supply of
high-quality, locally grown and sold, medical cannabis for the
country's expanding patient base.
"Aurora is proud to deliver to the rapidly growing German market
our first domestically produced medical cannabis product – a
significant step forward since Germany's move to decriminalize cannabis
earlier this year," says Michael
Simon, President, Aurora
Europe (Interim). "As one of three facilities licensed to
cultivate in Germany, we are
uniquely positioned to offer domestic product from our EU-GMP
facility in Leuna, Germany, which
operates within Aurora's global manufacturing network. It is
through our expertise in cultivation and deep commitment to science
and innovation that we introduce IndiMed to the German
patients."
The premium product launching from the IndiMed brand is Island
Sweet Skunk, dried flower, sativa, 20% THC, <1 % CBD. Product is
expected to be available on January
27. IndiMed is cultivated under GACP and EU-GMP guidelines
to ensure pharmaceutical-grade quality. The flowers are harvested
by hand, dried under controlled conditions, and tested in the
state-of-the-art laboratory for purity and active ingredient
content.
Aurora leads the global medical cannabis industry with unmatched
expertise, driving innovation and progress. Its steadfast
commitment to growth in the dynamic German market cements its
position as the industry's unrivaled leader.
Aurora's expertise in navigating complex European regulatory
frameworks and manufacturing high-quality medical cannabis
positions the company as the preferred leader to drive progress in
the German market with confidence. By continually setting new
global benchmarks, Aurora reinforces its status as the world's
largest medical cannabis company operating in nationally legal
markets.
About Aurora Cannabis Inc.
Aurora is opening the world to cannabis, serving both the
medical and consumer markets across Canada, Europe, Australia and South
America. Headquartered in Edmonton, Alberta, Aurora is a pioneer in
global cannabis, dedicated to helping people improve their lives.
The Company's adult-use brand portfolio includes Drift, San Rafael
'71, Daily Special, Tasty's, Being and Greybeard. Medical cannabis
brands include MedReleaf, CanniMed, Aurora and Whistler Medical
Marijuana Co., as well as international brands, Pedanios, IndiMed
and CraftPlant. Aurora also has a controlling interest in Bevo
Farms Ltd., North America's
leading supplier of propagated agricultural plants. Driven by
science and innovation, and with a focus on high-quality cannabis
products, Aurora's brands continue to break through as industry
leaders in the medical, wellness and adult recreational markets
wherever they are launched. Learn more at
www.auroramj.com and follow us
on X and LinkedIn.
Aurora's common shares trade on the NASDAQ and TSX under the
symbol
"ACB".
Forward Looking Information
This news release includes statements containing certain
"forward-looking information" within the meaning of applicable
securities law ("forward-looking statements").
Forward-looking statements are frequently characterized by words
such as "plan", "continue", "expect", "project", "intend",
"believe", "anticipate", "estimate", "may", "will", "potential",
"proposed" and other similar words, or statements that certain
events or conditions "may" or "will" occur. Forward-looking
statements made in this news release include, but are not limited
to, statements regarding the launch of the Company's first
German-cultivated medical cannabis product under the brand IndiMed,
the timing for availability of that product in the German market,
the Company's market leadership and status as the world's largest
medical cannabis company operating in nationally legal markets, and
the Company's ability to drive progress in the German market.
These forward-looking statements are only predictions. Forward
looking information or statements contained in this news release
have been developed based on assumptions management considers to be
reasonable. Material factors or assumptions involved in developing
forward-looking statements include, without limitation, publicly
available information from governmental sources as well as from
market research and industry analysis and on assumptions based on
data and knowledge of this industry which the Company believes to
be reasonable. Forward-looking statements are subject to a variety
of risks, uncertainties and other factors that management believes
to be relevant and reasonable in the circumstances could cause
actual events, results, level of activity, performance, prospects,
opportunities or achievements to differ materially from those
projected in the forward-looking statements. These risks include,
but are not limited to, the ability to retain key personnel, the
ability to continue investing in infrastructure to support growth,
the ability to obtain financing on acceptable terms, the continued
quality of our products, customer experience and retention, the
development of third party government and non-government consumer
sales channels, management's estimates of consumer demand in
Canada and in jurisdictions where
the Company exports, expectations of future results and expenses,
the risk of successful integration of acquired business and
operations (with respect to the Transaction and more generally with
respect to future acquisitions), management's estimation that
SG&A will grow only in proportion of revenue growth, the
ability to expand and maintain distribution capabilities, the
impact of competition, the general impact of financial market
conditions, the yield from cannabis growing operations, product
demand, changes in prices of required commodities, competition, and
the possibility for changes in laws, rules, and regulations in the
industry, epidemics, pandemics or other public health crises and
other risks, uncertainties and factors set out under the heading
"Risk Factors" in the Company's annual information from dated
June 20, 2024 (the "AIF") and filed
with Canadian securities regulators available on the Company's
issuer profile on SEDAR+ at www.sedarplus.com and filed with and
available on the SEC's website at www.sec.gov. The Company cautions
that the list of risks, uncertainties and other factors described
in the AIF is not exhaustive and other factors could also adversely
affect its results. Readers are urged to consider the risks,
uncertainties and assumptions carefully in evaluating the
forward-looking statements and are cautioned not to place undue
reliance on such information. The Company is under no obligation,
and expressly disclaims any intention or obligation, to update or
revise any forward-looking statements, whether as a result of new
information, future events or otherwise, except as expressly
required by applicable securities law.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/aurora-cannabis-launches-first-domestically-grown-medical-cannabis-brand-in-germany-under-new-cultivation-license-302357848.html
SOURCE Aurora Cannabis Inc.
